Annual Reports

FDA’s Office of Generic Drugs (OGD) reports annually on its accomplishments and organization. The reports include a Director’s Message summarizing the year’s activities, data on improved efficiency and recent progress toward Generic Drug User Fee Program (GDUFA) performance goals and commitments, an overview of new guidances and standards, highlights of the latest FDA efforts to communicate with industry and stakeholders, the year’s significant first generic drug approvals, and GDUFA regulatory science plan priorities for the year.

Page Last Updated: 02/27/2019
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English